A few weeks ago, Chandra Slusser represented Zealand Pharma at the The Oley Foundation's annual conference. Having the opportunity to hear from experts and those living with home IV nutrition or tube feeding was an invaluable experience. This year's conference focused on the importance of connection for support, education, advocacy, and industry innovation. It featured: - expert presentations & talks - community engagement activities - and plenty of fun plus acknowledging all the industry leaders that support the Oley Foundation We seek to change the lives of people living with unmet medical needs and their families and caregivers. It is these communities that are at the heart of everything we do. That is why we dedicate time and resources to meeting these communities face to face and working with thought leaders and area experts to increase our capabilities to positively impact as many people as possible. Learn more about the Oley Foundation and the important work they do for people living with home IV nutrition or tube feeding: https://oley.org/
Zealand Pharma
Forskning inden for bioteknologi
Changing lives with next generation peptide therapeutics
Om os
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a Danish biotechnology company on a mission to change lives with next generation peptide medicines. In our effort to reach our goals bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other. This has led to more than 10 drug candidates invented by Zealand having advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Additionally, the portfolio includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals. Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn or Twitter @ZealandPharma.
- Websted
-
http://www.zealandpharma.com
Eksternt link til Zealand Pharma
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 201-500 medarbejdere
- Hovedkvarter
- Søborg (Copenhagen)
- Type
- Aktieselskab
- Grundlagt
- 1998
Beliggenheder
Medarbejdere hos Zealand Pharma
Opdateringer
-
Have you visited our website recently? You may notice it looks a little different 🔎 If you haven’t checked it out, have a look and let us know what you think: www.zealandpharma.com We hope you can find what you’re looking for, but if not, reach out via our contact form and let us know how we can help!
-
Recently, a group of Zealanders gathered in Orlando to attend the 2024 American Diabetes Association Scientific Sessions and what a conference it was! Our team not only got to share insights and present data, but also participate in discussions and learn from other disease area experts and key opinion leaders. Some of the key highlights from the meeting were: ⭐ Positive trend in obesity being recognized as a global disease ⭐ Great talks about reducing the stigma around overweight and obesity ⭐ There is a trend towards treating overall health in people with overweight and obesity, and not a sole focus on the disease Thank you to all the Zealanders that could attend, we couldn’t do it without you: Evan C. Frary MD, JD, Chandra Slusser, John Sink II, Bill Vestergaard, Stanislava Macura, Thue Johansen, Mette Svendgaard, Mette Hammer, Nancy Hunter, Louise Dalgas Høeg and Ivan Moller
-
Zealand Pharma is pleased to announce gross proceeds of USD 1 billion (DKK 7 billion) raised through the completion of an upsized equity offering of 8,350,000 new shares to institutional and professional investors. Zealand expects the proceeds to provide funding to advance the clinical pipeline and reach several potential key milestones. Learn more about our programs and research on our website: https://lnkd.in/eEimU4xd We would like to thank the dedicated Zealanders who work hard to advance our peptide-based therapies to people who need them, the clinical sites, medical staff, and study participants involved in our trials, and finally, our shareholders for their continued support.
-
The verdict is in: Zealand Pharma ranks 2nd for best image among 37 large and trend-setting Life Science companies in Denmark. 🏅 Earlier this year, MedWatch surveyed nearly 4000 people in Denmark to uncover perceptions about major companies in pharmaceuticals and medical device. The survey participants were both people working in Life Science and people from the general public. We are proud to see that Zealanders are proud to work here. We couldn’t do it without them! Alongside our overall 2nd place ranking, Zealand Pharma had the greatest improvement overall and was ranked #1 for involving employees in making important decisions. Interested in joining our team? Check out our open positions: https://lnkd.in/dqg5c-Sh Learn more about the report here: https://lnkd.in/dC7VcgvU
-
Last night, Zealand Pharma attended the European Mediscience Awards 2024 and we are proud to share that we were nominated in three categories and awarded "Company of the Year." 🎉 Thank you to everyone at Zealand who has made this possible and thank you to Christina Sonnenborg Bredal and Ivan Moller for being there to represent Zealand. To be nominated, a company must be a well-managed, soundly financed growth business with a well-defined strategy to deliver its key financial, ethical, and social ambitions. Learn more about the awards here: https://lnkd.in/gaWTxaji
-
Today, Adam Steensberg, Zealand Pharma CEO, will be speaking at the Jefferies Global Healthcare Conference in New York. Register to watch his fireside chat at 10:00 EST / 16:00 CET: https://lnkd.in/duipBHcT
-
Zealand Pharma reports a strong financial and business performance in the first quarter of 2024. For more details on R&D activities and upcoming events, read the full financial report: https://lnkd.in/dTtKzXqN You can also tune into Zealand’s conference call today at 2:00 PM CET / 8:00 AM ET, where our management team (Adam Steensberg, Henriette Wennicke, and David Kendall) will present results from the first three months of 2024 followed by a Q&A session. Join the session here: https://lnkd.in/dwhmAEME
-
Today we're nearly 300 Zealanders and we're still growing 🌱 If you're interested in joining our team here at Zealand making new bonds, check out our open positions: https://lnkd.in/eQ65mBR6 Don't see a match right now? Be sure to keep an eye out for future open positions by following us here at Zealand Pharma
Tilsvarende sider
Finansiering
Seneste runde
Post IPO-egenkapital1.007.265.115,00 US$